SCHEMBL73050

SCHEMBL73050

CCCCCCCCCCCCCCCCCCN(C)CC(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 6/20 0.54
KDM5A P29375 4/20 0.54
PHF8 Q9UPP1 2/20 0.54
KDM5C P41229 1/20 0.51
KDM5B Q9UGL1 1/20 0.51
KDM4A O75164 2/20 0.50
S1PR2 O95136 1/20 0.50
S1PR1 P21453 1/20 0.50
S1PR3 Q99500 1/20 0.50
S1PR5 Q9H228 1/20 0.50
GPR84 Q9NQS5 7/20 0.48
PPARG P37231 7/20 0.48
PPARD Q03181 7/20 0.48
PPARA Q07869 7/20 0.48
HDAC11 Q96DB2 5/20 0.48
TSHR P16473 4/20 0.48
PTPN1 P18031 3/20 0.48
ALDH1A1 P00352 2/20 0.48
TLR2 O60603 2/20 0.48
TDP1 Q9NUW8 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8093289 1.00 KDM4C (0.54) KDM4CKDM5APHF8KDM5CKDM5B
SCHEMBL5984529 1.00 KDM4C (0.54) KDM4CKDM5APHF8KDM5CKDM5B
SCHEMBL28942179 1.00 KDM4C (0.54) KDM4CKDM5APHF8KDM5CKDM5B
SCHEMBL448290 1.00 KDM4C (0.54) KDM4CKDM5APHF8KDM5CKDM5B
SCHEMBL16895244 1.00 KDM4C (0.54) KDM4CKDM5APHF8KDM5CKDM5B
SCHEMBL41611 1.00 KDM4C (0.54) KDM4CKDM5APHF8KDM5CKDM5B
SCHEMBL5984033 1.00 KDM4C (0.54) KDM4CKDM5APHF8KDM5CKDM5B
SCHEMBL10610457 1.00 KDM4C (0.54) KDM4CKDM5APHF8KDM5CKDM5B
SCHEMBL1272817 1.00 KDM4C (0.54) KDM4CKDM5APHF8KDM5CKDM5B
SCHEMBL27082196 1.00 KDM4C (0.54) KDM4CKDM5APHF8KDM5CKDM5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2317 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4716693-A2 PHARMACEUTICAL COMPOSITIONS FOR ANTIBODIES AND MAKING AND USING THE SAME INVETX, INC. (US) 2026-04-01 EP claimed
EP-4021643-B1 A COLLECTOR COMPOSITION FOR THE LITHIUM ORE OR MAGNESIUM ORE FLOTATION BASF SE (DE) 2025-12-03 EP claimed
US-12478982-B2 Collector composition BASF SE (DE) 2025-11-25 US claimed
EP-4642492-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 EP claimed
EP-4642484-A1 TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 EP claimed
WO-2024243322-A9 PHARMACEUTICAL COMPOSITIONS FOR ANTIBODIES AND MAKING AND USING THE SAME INVETX, INC. (US) 2025-03-27 WO claimed
US-20250073319-A1 LYOPHILIZED ENPP1 POLYPEPTIDE FORMULATIONS AND USES THEREOF BIOMARIN PHARMACEUTICAL INC. 2025-03-06 US claimed
US-20240398825-A1 MELOXICAM COMPOSITION, PHARMACEUTICAL PREPARATION, AND PREPARATION METHOD AND USE THEREOF NANJING DELOVA BIOTECH CO., LTD. (CN) 2024-12-05 US claimed
US-20240392009-A1 PHARMACEUTICAL COMPOSITIONS FOR ANTIBODIES AND MAKING AND USING THE SAME INVETX INC (US) 2024-11-28 US claimed
WO-2024240173-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) 2024-11-28 WO claimed
US-20180000932-A1 FORMULATION OF AGLYCOSYLATED THERAPEUTIC ANTIBODIES NOVELMED THERAPEUTICS INC (US) 2018-01-04 US claimed
EP-3240571-A1 FORMULATION OF AGLYCOSYLATED THERAPEUTIC ANTIBODIES NovelMed Therapeutics, Inc. (US) 2017-11-08 EP claimed
EP-2585105-B1 TREATMENT OF SANFILIPPO SYNDROME TYPE B SHIRE HUMAN GENETIC THERAPIES (US) 2017-08-09 EP claimed
CN-106726670-A A kind of skin protection cosmetics comprising N acyl aminos hydrochlorate/plant peptide combinations and preparation method thereof 长沙普济生物科技股份有限公司 2017-05-31 CN claimed
CN-106491380-A Special N acylamino acids anion surfactant type mildy wash/cream of a kind of face cleaning instrument and preparation method thereof 长沙普济生物科技股份有限公司 2017-03-15 CN claimed
US-20160263223-A1 STABLE SUBCUTANEOUS PROTEIN FORMULATIONS AND USES THEREOF BRISTOL MYERS SQUIBB CO (US) 2016-09-15 US claimed
EP-3048899-A2 ON-COLUMN VIRAL INACTIVATION METHODS Biogen MA Inc. (US) 2016-08-03 EP claimed
WO-2016109822-A1 FORMULATION OF AGLYCOSYLATED THERAPEUTIC ANTIBODIES NOVELMED THERAPEUTICS, INC. (US) 2016-07-07 WO claimed
US-9309316-B2 Stable subcutaneous protein formulations and uses thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2016-04-12 US claimed
WO-2015048330-A2 ON-COLUMN VIRAL INACTIVATION METHODS BIOGEN IDEC MA INC. (US) 2015-04-02 WO claimed